Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director

Reuters03-27

Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director

Non-executive director Ni Jia resigned, effective March 27, 2026.
The board nominated Wu Fenglan as a non-executive director, subject to shareholder approval at the AGM.
Wu previously served as a scientist at GlaxoSmithKline, and later held roles at Zai Lab, China Renaissance, and Gritgen Therapeutics.
She joined Shanghai Zhengxingu Investment Management in October 2025 as a managing director focused on innovative drug investments.
Nomination Committee member Zhang Hongbing was appointed chair, replacing Kang Xiaoqiang who remains a committee member.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072930), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622284948?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 18:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622284948","market":"us","top_or_hot":-1,"title":"Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Non-executive director Ni Jia resigned, effective March 27, 2026.\n        </li>\n<li>\n          The board nominated Wu Fenglan as a non-executive director, subject to shareholder approval at the AGM.\n        </li>\n<li>\n          Wu previously served as a scientist at GlaxoSmithKline, and later held roles at <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a>, <a href=\"https://laohu8.com/S/CSCHF\">China Renaissance</a>, and Gritgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>.\n        </li>\n<li>\n          She joined Shanghai Zhengxingu Investment Management in October 2025 as a managing director focused on innovative drug investments.\n        </li>\n<li>\n          Nomination Committee member Zhang Hongbing was appointed chair, replacing Kang Xiaoqiang who remains a committee member.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072930), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-27 18:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Non-executive director Ni Jia resigned, effective March 27, 2026.\n        </li>\n<li>\n          The board nominated Wu Fenglan as a non-executive director, subject to shareholder approval at the AGM.\n        </li>\n<li>\n          Wu previously served as a scientist at GlaxoSmithKline, and later held roles at <a href=\"https://laohu8.com/S/ZAILF\">Zai Lab</a>, <a href=\"https://laohu8.com/S/CSCHF\">China Renaissance</a>, and Gritgen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>.\n        </li>\n<li>\n          She joined Shanghai Zhengxingu Investment Management in October 2025 as a managing director focused on innovative drug investments.\n        </li>\n<li>\n          Nomination Committee member Zhang Hongbing was appointed chair, replacing Kang Xiaoqiang who remains a committee member.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072930), on March 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1015430645.USD","symbol_name":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2Y01zT:1","article_id":"2622284948","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622284948","pubTimestamp":1774608885,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Non-executive director Ni Jia resigned, effective March 27, 2026.The board nominated Wu Fenglan as a non-executive director, subject to shareholder approval at the AGM.Wu previously served as a scientist at GlaxoSmithKline, and later held roles at Zai Lab, China Renaissance, and Gritgen Therapeutics.She joined Shanghai Zhengxingu Investment Management in October 2025 as a managing director focused on innovative drug investments.Nomination Committee member Zhang Hongbing was appointed chair, replacing Kang Xiaoqiang who remains a committee member.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated b","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1015430645.USD":"SCHRODER ISF UK EQUITY \"A\" (USDHDG) ACC","09688":"再鼎医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1645745479.HKD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (HKDHDG) INC","LU0971552673.USD":"Allianz European Equity Dividend Cl AM DIS H2-USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU1035777561.USD":"AB SICAV I - EUROPEAN EQUITY PORTFOLIO \"A\" (USDHDG) ACC","LU1400636491.USD":"Allianz Europe Income and Growth Cl AMg DIS H2-USD","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1400636657.SGD":"Allianz Europe Income and Growth Cl AMg DIS H2-SGD","LU1481600234.SGD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"ASC\" (SGDHDG) INC","LU1228905037.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) ACC","IE00BQJZX424.USD":"FRANKLIN MV EUROPEAN EQUITY GROWTH AND INCOME \"A\" (USDHDG) INC","09887":"维立志博-B","BK1588":"回港中概股","IE00BWDBJ516.SGD":"Legg Mason QS - MV European Equity Growth and Income A Mdis SGD-H Plus","BK1161":"生物科技","LU1046248800.SGD":"Allianz European Equity Dividend Cl AM DIS H2-SGD","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0161305163.EUR":"SCHRODER ISF EUROPEAN VALUE \"A\" (EUR) ACC","LU0575583348.USD":"SCHRODER ISF UK EQUITY \"A\" (USD) INC AV","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1202635105.USD":"ALLIANZ EUROPE INCOME AND GROWTH \"AM\" (USDHDG) INC","LU1228905540.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC 2","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU1064927863.SGD":"JPMorgan Funds - Europe Dynamic A (acc) SGD-H","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1670756490.USD":"ALLIANZ EUROPE INCOME AND GROWTH \"AT\" (USDHDG) ACC","LU0109981661.USD":"FRANKLIN MUTUAL EUROPEAN \"A\" (USD) ACC","BK1574":"生物医药B类股","LU1302929846.USD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AMG\" (USDHDG) INC","GSK.UK":"葛兰素史克","LU1309081286.SGD":"SCHRODER ISF EUROPEAN VALUE \"A\" (SGDHDG) ACC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","IE0034235071.USD":"PINEBRIDGE EUROPE RESEARCH ENHANCED EQUITY \"A\" (USD) ACC","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","SG9999001176.USD":"United Global Healthcare Acc USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","LU0971552830.HKD":"ALLIANZ EUROPEAN EQUITY DIVIDEND \"AM\" (HKDHDG) INC","LU0545562505.USD":"NINETY ONE GSF GLOBAL QUALITY DIVIDEND GROWTH \"A\" (USD) INC","LU1481599808.USD":"THREADNEEDLE (LUX) UK EQUITY INCOME \"AUC\" (USDHDG) INC"},"translate_title":"南京领创生物非执行董事倪佳辞职；吴凤兰提名为非执行董事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.9,"09887":0.9,"09688":0.9},"content_text":"Nanjing Leads Biolabs non-executive director Ni Jia resigns; Wu Fenglan nominated as non-executive director\n    \n\n\n          Non-executive director Ni Jia resigned, effective March 27, 2026.\n        \n\n          The board nominated Wu Fenglan as a non-executive director, subject to shareholder approval at the AGM.\n        \n\n          Wu previously served as a scientist at GlaxoSmithKline, and later held roles at Zai Lab, China Renaissance, and Gritgen Therapeutics.\n        \n\n          She joined Shanghai Zhengxingu Investment Management in October 2025 as a managing director focused on innovative drug investments.\n        \n\n          Nomination Committee member Zhang Hongbing was appointed chair, replacing Kang Xiaoqiang who remains a committee member.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260327-12072930), on March 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622284948","isCrawlerRequest":true}